Document is current
Any future updates will be listed below
-
Authors
Wallings, Rebecca L.
Gillett, Drew A.
Staley, Hannah A.
Mahn, Savanna
Mark, Julian
Neighbarger, Noelle
Kordasiewicz, Holly
Hirst, Warren D.
Tansey, Malú Gámez
-
Funding
Funding for this research was provided by:
BrightFocus Foundation
National Institute of Neurological Disorders and Stroke (RF1NS128800)
Parkinson's Disease Foundation (PF-LAUNCH-1263938)
- License Information
-
More Information
Article History
Received: 22 July 2024
Accepted: 14 March 2025
First Online: 8 April 2025
Declarations
:
: This study was reviewed and approved by the University of Florida Institutional Review Board (IRB202101359). All patient samples were obtained from NCRAD (see funding details below), and all participants provided informed consent in their respective cohort studies. This study was reviewed and approved by the University of Florida Institutional Animal Care and Use Committee (IACUC202200000114).
: Not applicable.
: MGT is a current or recent advisor/consultant for INmune Bio, Merck, Alnylam, Astex Pharmaceuticals, Arvinas, Therapeutics, Forward Therapeutics, Weston Foundation, Alzheimer’s Association, Bright Focus Foundation, New Horizons Research, SciNeuro, NysnoBio, Longevity, Longeveron, iMetabolic Pharma, Novo Nordisk, Cellestial Health, iMMvention and Jaya. MGT is EIC for NPJ Parkinson’s Disease. WDH is an employee of Biogen and HK is an employee of Ionis Pharmaceuticals where ASOs are currently under development for neurological indications. All other authors hold no competing interests.
